Category: M&A / Deals
PharmaSignal — M&A / Deals
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Pharmaceutical Business Review
Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee.
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
PharmaTimes
Partnership to develop nextgeneration Tcell engagers for solid tumours
Roche sticks with C4T, adding up to $1B for molecular glue partnership
BioSpace
Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb.
Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors
BioSpace
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.
EverSea Medicines to acquire Hasten Biopharmaceuticals
Pharmaceutical Business Review
The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets.
Jeito Capital secures over $1.2bn for new biopharma investments
Pharmaceutical Business Review
The milestone increases Jeito’s assets under management to 1.6bn, following the 534m closure of Jeito I in 2021.
Syneron raises $150m for macrocyclics, and other financings
Pharmaphorum
Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
Shionogi secures $482m BARDA contract to tackle AMR crisis
Pharmaceutical Technology
Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.
Sidewinder secures $137M to advance ‘precision’ ADCs
BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
With 3 quick buyouts, Gilead leans into its latest transformation
BioPharma Dive
On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune conditions could help a diversification plan it s long struggled to execute.
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities
BioSpace
Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M A pace.
Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Pharmaceutical Technology
The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.
Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data
BioSpace
Another bidder, which remains unidentified, dropped out of the bidding process.
RoosterBio and MineBio team up to expand MSC solutions access in China
Pharmaceutical Business Review
MineBio will supply RoosterBio’s complete platform of products, having already obtained import clearance.
Halozyme and Vertex sign deal for Hypercon technology
Pharmaceutical Business Review
Vertex has licensed the technology for use in up to three drug targets, as part of the agreement.
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis
BioPharma Dive
Gilead s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple prospects already in clinical testing.
Gilead outlays $5bn to acquire ADC specialist Tubulis
Pharmaceutical Technology
Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
BioSpace
The acquisition of Tubulis GmbH–Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines–brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-st
Gilead strikes again, penning $5bn deal to buy Tubulis
Pharmaphorum
Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
AI giant Anthropic buys Coefficient Bio for $400m
Pharmaphorum
Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.